BIOMAT Database Logo BIOMAT Database Logo

FEIBA in haemophiliacs with factor VIII inhibitor. 1977

T Thomas, and H Williams, and Y Williams, and J Hunt

UI MeSH Term Description Entries
D008297 Male Males
D003029 Coagulants Agents that cause clotting. Coagulant
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Thomas, and H Williams, and Y Williams, and J Hunt
Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors.
November 1977, Thrombosis research,
T Thomas, and H Williams, and Y Williams, and J Hunt
Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.
January 2008, Haemophilia : the official journal of the World Federation of Hemophilia,
T Thomas, and H Williams, and Y Williams, and J Hunt
Long-term high dose factor VIII treatment of 3 haemophiliacs with factor VIII inhibitor.
May 1985, Scandinavian journal of haematology,
T Thomas, and H Williams, and Y Williams, and J Hunt
Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA.
January 2009, Haemophilia : the official journal of the World Federation of Hemophilia,
T Thomas, and H Williams, and Y Williams, and J Hunt
Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.
August 1993, Lancet (London, England),
T Thomas, and H Williams, and Y Williams, and J Hunt
Factor VIII inhibitors in haemophiliacs.
July 1992, Lancet (London, England),
T Thomas, and H Williams, and Y Williams, and J Hunt
Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
January 1980, Acta haematologica,
T Thomas, and H Williams, and Y Williams, and J Hunt
Factor VIII and factor IX inhibitors in haemophiliacs.
June 1992, Lancet (London, England),
T Thomas, and H Williams, and Y Williams, and J Hunt
Factor VIII and factor IX inhibitors in haemophiliacs.
June 1992, Lancet (London, England),
T Thomas, and H Williams, and Y Williams, and J Hunt
Apparent intrinsic prothrombinase activity of human Factor X zymogen: identification with Factor VIII inhibitor bypassing activity (FEIBA).
December 1984, Thrombosis research,
Copied contents to your clipboard!